vs

Side-by-side financial comparison of Forafric Global PLC (AFRI) and Bioventus Inc. (BVS). Click either name above to swap in a different company.

Forafric Global PLC is the larger business by last-quarter revenue ($159.7M vs $157.9M, roughly 1.0× Bioventus Inc.). Bioventus Inc. runs the higher net margin — 9.3% vs -7.5%, a 16.9% gap on every dollar of revenue. Bioventus Inc. produced more free cash flow last quarter ($37.4M vs $146.0K).

Forafric Global PLC is an Africa-focused agribusiness operating across the full agricultural value chain, covering staple food production, processing, and distribution. Its core markets are North and West Africa, supplying grain, vegetable oil and essential food commodities to consumer, retail and industrial clients.

Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.

AFRI vs BVS — Head-to-Head

Bigger by revenue
AFRI
AFRI
1.0× larger
AFRI
$159.7M
$157.9M
BVS
Higher net margin
BVS
BVS
16.9% more per $
BVS
9.3%
-7.5%
AFRI
More free cash flow
BVS
BVS
$37.2M more FCF
BVS
$37.4M
$146.0K
AFRI

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
AFRI
AFRI
BVS
BVS
Revenue
$159.7M
$157.9M
Net Profit
$-12.0M
$14.8M
Gross Margin
10.7%
68.9%
Operating Margin
-2.5%
12.3%
Net Margin
-7.5%
9.3%
Revenue YoY
2.8%
Net Profit YoY
3902.8%
EPS (diluted)
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AFRI
AFRI
BVS
BVS
Q4 25
$157.9M
Q3 25
$138.7M
Q2 25
$159.7M
$147.7M
Q1 25
$123.9M
Q4 24
$153.6M
Q3 24
$139.0M
Q2 24
$145.6M
$151.2M
Q1 24
$129.5M
Net Profit
AFRI
AFRI
BVS
BVS
Q4 25
$14.8M
Q3 25
$3.2M
Q2 25
$-12.0M
$7.5M
Q1 25
$-2.6M
Q4 24
$-388.0K
Q3 24
$-5.2M
Q2 24
$-8.6M
$-25.7M
Q1 24
$-4.9M
Gross Margin
AFRI
AFRI
BVS
BVS
Q4 25
68.9%
Q3 25
68.0%
Q2 25
10.7%
69.1%
Q1 25
67.0%
Q4 24
66.8%
Q3 24
67.3%
Q2 24
9.4%
68.5%
Q1 24
68.3%
Operating Margin
AFRI
AFRI
BVS
BVS
Q4 25
12.3%
Q3 25
8.1%
Q2 25
-2.5%
12.4%
Q1 25
3.9%
Q4 24
5.0%
Q3 24
2.6%
Q2 24
-0.9%
-20.8%
Q1 24
3.8%
Net Margin
AFRI
AFRI
BVS
BVS
Q4 25
9.3%
Q3 25
2.3%
Q2 25
-7.5%
5.1%
Q1 25
-2.1%
Q4 24
-0.3%
Q3 24
-3.7%
Q2 24
-5.9%
-17.0%
Q1 24
-3.8%
EPS (diluted)
AFRI
AFRI
BVS
BVS
Q4 25
$0.21
Q3 25
$0.05
Q2 25
$0.11
Q1 25
$-0.04
Q4 24
$0.00
Q3 24
$-0.08
Q2 24
$-0.40
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AFRI
AFRI
BVS
BVS
Cash + ST InvestmentsLiquidity on hand
$12.2M
$51.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.3M
$184.1M
Total Assets
$246.1M
$683.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AFRI
AFRI
BVS
BVS
Q4 25
$51.2M
Q3 25
$42.2M
Q2 25
$12.2M
$32.9M
Q1 25
$22.8M
Q4 24
$41.6M
Q3 24
$43.1M
Q2 24
$16.4M
$32.0M
Q1 24
$25.2M
Total Debt
AFRI
AFRI
BVS
BVS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$18.4M
Q1 24
Stockholders' Equity
AFRI
AFRI
BVS
BVS
Q4 25
$184.1M
Q3 25
$166.1M
Q2 25
$5.3M
$161.2M
Q1 25
$148.1M
Q4 24
$147.9M
Q3 24
$148.7M
Q2 24
$16.3M
$150.9M
Q1 24
$171.3M
Total Assets
AFRI
AFRI
BVS
BVS
Q4 25
$683.6M
Q3 25
$701.6M
Q2 25
$246.1M
$706.8M
Q1 25
$691.4M
Q4 24
$728.0M
Q3 24
$769.5M
Q2 24
$287.1M
$792.2M
Q1 24
$794.2M
Debt / Equity
AFRI
AFRI
BVS
BVS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
1.13×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AFRI
AFRI
BVS
BVS
Operating Cash FlowLast quarter
$706.0K
$38.0M
Free Cash FlowOCF − Capex
$146.0K
$37.4M
FCF MarginFCF / Revenue
0.1%
23.7%
Capex IntensityCapex / Revenue
0.4%
0.4%
Cash ConversionOCF / Net Profit
2.57×
TTM Free Cash FlowTrailing 4 quarters
$72.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AFRI
AFRI
BVS
BVS
Q4 25
$38.0M
Q3 25
$30.1M
Q2 25
$706.0K
$25.9M
Q1 25
$-19.3M
Q4 24
$19.3M
Q3 24
$10.3M
Q2 24
$10.5M
$15.2M
Q1 24
$-6.0M
Free Cash Flow
AFRI
AFRI
BVS
BVS
Q4 25
$37.4M
Q3 25
$29.6M
Q2 25
$146.0K
$25.3M
Q1 25
$-20.2M
Q4 24
$18.7M
Q3 24
$10.3M
Q2 24
$6.4M
$15.1M
Q1 24
$-6.3M
FCF Margin
AFRI
AFRI
BVS
BVS
Q4 25
23.7%
Q3 25
21.4%
Q2 25
0.1%
17.1%
Q1 25
-16.3%
Q4 24
12.2%
Q3 24
7.4%
Q2 24
4.4%
10.0%
Q1 24
-4.9%
Capex Intensity
AFRI
AFRI
BVS
BVS
Q4 25
0.4%
Q3 25
0.3%
Q2 25
0.4%
0.5%
Q1 25
0.7%
Q4 24
0.4%
Q3 24
0.0%
Q2 24
2.8%
0.1%
Q1 24
0.2%
Cash Conversion
AFRI
AFRI
BVS
BVS
Q4 25
2.57×
Q3 25
9.54×
Q2 25
3.48×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AFRI
AFRI

Sales to external customers, Total$159.7M100%
Couscous & Pasta$934.0K1%
Soft Wheat$393.0K0%

BVS
BVS

Pain Treatments$71.1M45%
Surgical Solutions$48.9M31%
Restorative Therapies$19.5M12%
Other$18.4M12%

Related Comparisons